1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  05/20 11:30:37 am EDT
319.70 CHF   +0.88%
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimilar, in Canada
AQ
05/20Cancer coalition aims to boost access to medicines in poorer countries
RE
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Launches Cobas Pulse System

01/12/2022 | 01:00am EDT

Roche announced the launch of the cobas® pulse system in select countries accepting the CE Mark. The cobas® pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management. As an industry first, the cobas® pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities similar to that of a smartphone. Glucose is among the most important biomarkers to assess patient health and predict, diagnose and manage metabolic disorders. In particular, the management of blood glucose in patients is critical to preventing acute and chronic complications that may lead to increased morbidity, mortality and healthcare costs. Against the backdrop of a rising epidemic of diabetes and other non-communicable diseases, the need to regularly perform this critical intervention adds to an ever-growing list of responsibilities facing stretched healthcare systems and professionals. Designed for professional use in a range of care settings where timely and informed clinical decisions are needed, the cobas® pulse system introduces several advancements that aim to drastically simplify workflows for busy nurses and doctors and improve their ability to deliver care at the bedside.


© S&P Capital IQ 2022
All news about ROCHE HOLDING AG
05/20Biocon Biologics and Viatris Launch Abevmy (bBevacizumab), Their Third Oncology Biosimi..
AQ
05/20Cancer coalition aims to boost access to medicines in poorer countries
RE
05/19ROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
05/17AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
05/16TRANSCRIPT : Roche Holding AG - Special Call
CI
05/13PUMP / DUMP #31 : The week's gainers and losers
05/13ROCHE HOLDINGS AG : Reduced to Neutral by Jefferies
MD
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/12ROCHE HOLDINGS AG : Gets a Neutral rating from Morgan Stanley
MD
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 028 M 65 632 M 65 632 M
Net income 2022 14 979 M 15 354 M 15 354 M
Net Debt 2022 11 180 M 11 460 M 11 460 M
P/E ratio 2022 17,1x
Yield 2022 3,04%
Capitalization 260 B 267 B 267 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,06x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 319,70 CHF
Average target price 396,90 CHF
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.67%266 707
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
NOVO NORDISK A/S3.58%245 099